Targeting Mitochondrial Dysfunction
Our lead product, Imeglimin, is in Phase 3 development in Japan and has successfully completed Phase 2 development in the U.S. and EU.
View Candidate
Innovative Pipeline of First-In-Class Products
Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.
View Pipeline
Backed by Strong Leadership
Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.
Meet Our Team
Latest News
Poxel Announces Participation at the H.C. Wainwright 3rd Annual NASH Investor Conference
Presentation will include an overview of Poxel’s two clinical-stage programs for the treatment of NASH LYON, France--(BUSINESS WIRE)-- POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical…
Read this Press Release: Poxel Announces Participation at the H.C. Wainwright 3rd Annual NASH Investor ConferencePoxel Reports Financial Results for the Third Quarter and Nine Months 2019 and Provides Corporate Update
LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and…
Read this Press Release: Poxel Reports Financial Results for the Third Quarter and Nine Months 2019 and Provides Corporate UpdatePoxel Announces Detailed Imeglimin Phase 3 TIMES 1 Results Presented at 55th Annual Meeting of the European Association for the Study of Diabetes
Imeglimin results featured in symposium session with leading diabetes expert Ralph DeFronzo, M.D., discussing preclinical and clinical data supporting safety and efficacy of Imeglimin in various patient populations…
Read this Press Release: Poxel Announces Detailed Imeglimin Phase 3 TIMES 1 Results Presented at 55th Annual Meeting of the European Association for the Study of Diabetes
Upcoming Events
Licensing Executives Society (LES) 2019 Annual Meeting
HC Wainwright 3rd Annual NASH Investor Conference
BioNetwork Partnering Summit
Gilbert Dupont NASH Conference
American Association for the Study of Liver Diseases (AASLD) poster presentation for PXL065
Bio-Europe
William Blair Boston Innovation Day
China Healthcare Summit 2019, The Bridge to Innovation
Jefferies Global Healthcare Conference
World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease
